OOIR: Observatory of International Research

Papers

(The TQCC of Autoimmunity Reviews is 18. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-04-01 to 2024-04-01.)

Article	Citations
The Role of Cytokines including Interleukin-6 in COVID-19 induced Pneumonia and Macrophage Activation Syndrome-Like Disease	1240
Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in Brescia, Italy	570
Should we stimulate or suppress immune responses in COVID-19? Cytokine and anti-cytokine interventions	497
Covid-19 and autoimmunity	396
Convalescent plasma in Covid-19: Possible mechanisms of action	364
The SARS-CoV-2 as an instrumental trigger of autoimmunity	341
COVID-19 infection and rheumatoid arthritis: Faraway, so close!	312
Could Sars-coronavirus-2 trigger autoimmune and/or autoinflammatory mechanisms in genetically predisposed subjects?	212
COVID-19 gone bad: A new character in the spectrum of the hyperferritinemic syndrome?	205
Hashimoto's thyroiditis: An update on pathogenic mechanisms, diagnostic protocols, therapeutic strategies, and potential malignant transformation	201
Rheumatoid arthritis: Extra-articular manifestations and comorbidities	169
Corona (COVID-19) time musings: Our involvement in COVID-19 pathogenesis, diagnosis, treatment and vaccine planning	164
Immunomodulatory therapy for the management of severe COVID-19. Beyond the anti-viral therapy: A comprehensive review	151
The role of TH17 cells in multiple sclerosis: Therapeutic implications	142
Interleukin 1α: a comprehensive review on the role of IL-1α in the pathogenesis and treatment of autoimmune and inflammatory diseases	139
SARS-CoV-2, the autoimmune virus	138
Post-COVID syndrome. A case series and comprehensive review	137
Beyond the joints, the extra-articular manifestations in rheumatoid arthritis	136
Response to SARS-CoV-2 vaccination in immune mediated inflammatory diseases: Systematic review and meta-analysis	123
SARS-CoV-2 infection among patients with systemic autoimmune diseases	123
Tocilizumab for cytokine storm syndrome in COVID-19 pneumonia: an increased risk for candidemia?	117
CCR6-CCL20 axis as a therapeutic target for autoimmune diseases	97
The influence of cytokines on the complex pathology of ulcerative colitis	95
A Unifying Hypothesis of the Pathophysiology of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS): Recognitions from the finding of autoantibodies against ß2-adrenergic receptors	94
Clinical outcome measures in multiple sclerosis: A review	91

Molecular mimicry may explain multi-organ damage in COVID-19	89
B cell activating factor (BAFF): Structure, functions, autoimmunity and clinical implications in Systemic Lupus Erythematosus (SLE)	87
The IL-1 family cytokines and receptors in autoimmune diseases	86
An updated advance of autoantibodies in autoimmune diseases	86
Molecular mimicry between SARS-CoV-2 and respiratory pacemaker neurons	85
An Overview of the NF-kB mechanism of pathophysiology in rheumatoid arthritis, investigation of the NF-kB ligand RANKL and related nutritional interventions	85
Transcriptional landscape of SARS-CoV-2 infection dismantles pathogenic pathways activated by the virus, proposes unique sex-specific differences and predicts tailored therapeutic strategies	81
Immune checkpoint inhibitor-induced myositis, the earliest and most lethal complication among rheumatic and musculoskeletal toxicities	79
ACE2 at the centre of COVID-19 from paucisymptomatic infections to severe pneumonia	79
Rheumatoid arthritis in the elderly: Characteristics and treatment considerations	78
2020 international consensus on ANCA testing beyond systemic vasculitis	77
Novel insights into macrophage diversity in rheumatoid arthritis synovium	76
Worldwide trends in all-cause mortality of auto-immune systemic diseases between 2001 and 2014	76
Dysfunctional mitochondria as critical players in the inflammation of autoimmune diseases: Potential role in Sjögren’s syndrome	75
The autonomic aspects of the post-COVID19 syndrome	75
The effect of hydroxychloroquine on thrombosis prevention and antiphospholipid antibody levels in primary antiphospholipid syndrome: A pilot open label randomized prospective study	72
Rheumatological complications of Covid 19	71
Cytokine storm syndrome in severe COVID-19	67
Continuous hydroxychloroquine or colchicine therapy does not prevent infection with SARS-CoV-2: Insights from a large healthcare database analysis	66
Immune dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) syndrome: A systematic review	59
Autoantibodies and SARS-CoV2 infection: The spectrum from association to clinical implication: Report of the 15th Dresden Symposium on Autoantibodies	59
Role of interleukin-6 in bone destruction and bone repair in rheumatoid arthritis	57
The pre-clinical phase of rheumatoid arthritis: From risk factors to prevention of arthritis	55
Gender-related differences in systemic sclerosis	54
Exosomes: Effectual players in rheumatoid arthritis	54
The cytokine network in the pathogenesis of major depressive disorder. Close to translation?	52
Pathogenesis, clinical features, and treatment strategy for rheumatoid arthritis-associated interstitial lung disease	51
Update on IgG4-mediated autoimmune diseases: New insights and new family members	51
The role of T cells in pemphigus vulgaris and bullous pemphigoid	50
Clinical outcomes of COVID-19 in patients with rheumatic diseases: A systematic review and meta-analysis of global data	49
Neuropsychiatric involvement in systemic lupus erythematosus: A review	49
Efficacy and safety of abatacept in interstitial lung disease of rheumatoid arthritis: A systematic literature review	47
Autoantibodies in COVID-19: frequency and function	47
Interleukin-17A (IL-17A), a key molecule of innate and adaptive immunity, and its potential involvement in COVID-19-related thrombotic and vascular mechanisms	46
Clinical associations of renal involvement in ANCA-associated vasculitis	46
Rheumatic immune-related adverse events associated with cancer immunotherapy: A nationwide multi-center cohort	45
Risk of scleroderma according to the type of immune checkpoint inhibitors	43
Disease modifying therapies in relapsing-remitting multiple sclerosis: A systematic review and network meta-analysis	42
Glaucoma is an autoimmune disease	42
Low-dose Interleukin-2: Biology and therapeutic prospects in rheumatoid arthritis	41
Immunosenescence in multiple sclerosis: the identification of new therapeutic targets	41
Direct oral anticoagulants in antiphospholipid syndrome: Meta-analysis of randomized controlled trials	40
The roles of adenosine deaminase in autoimmune diseases	39
Relationship between disease activity, organ damage and health-related quality of life in patients with systemic lupus erythematosus: A systemic review and meta-analysis	39
Calcinosis Biomarkers in Adult and Juvenile Dermatomyositis	38
“Non-criteria” antiphospholipid syndrome: A nomenclature proposal	37
Rituximab in adult minimal change disease and focal segmental glomerulosclerosis - What is known and what is still unknown?	37
Pentraxin 3: A promising therapeutic target for autoimmune diseases	37
The growing role of precision medicine for the treatment of autoimmune diseases; results of a systematic review of literature and Experts’ Consensus	37
Autoimmunity roots of the thrombotic events after COVID-19 vaccination	37

Mucous membrane pemphigoid	37
Giant cell arteritis or polymyalgia rheumatica after influenza vaccination: A study of 12 patients and a literature review	37
Update in immunosuppressive therapy of myasthenia gravis	36
Immune checkpoint inhibitors-induced autoimmunity: The impact of gender	36
Working and safety profiles of JAK/STAT signaling inhibitors. Are these small molecules also smart?	35
Interplay of immune and kidney resident cells in the formation of tertiary lymphoid structures in lupus nephritis	35
Eculizumab use in catastrophic antiphospholipid syndrome (CAPS): Descriptive analysis from the “CAPS Registry”	35
Systematic review and meta-analysis of cardiovascular risk in rheumatological disease: Symptomatic and non-symptomatic events in rheumatoid arthritis and systemic lupus erythematosus	34
Rheumatic heart disease: A review of the current status of global research activity	34
Phoenix from the flames: Rediscovering the role of the CD40–CD40L pathway in systemic lupus erythematosus and lupus nephritis	34
Combination therapy in inflammatory bowel disease – from traditional immunosuppressors towards the new paradigm of dual targeted therapy	33
The value of anti-neutrophil cytoplasmic antibodies (ANCA) testing for the diagnosis of ANCA-associated vasculitis, a systematic review and meta-analysis	33
Precision medicine in the care of rheumatoid arthritis: Focus on prediction and prevention of future clinically-apparent disease	33
Autoimmune thyroid disorders and rheumatoid arthritis: A bidirectional interplay	33
Monocytes and macrophages in ANCA-associated vasculitis	33
Minor salivary gland biopsy: Its role in the classification and prognosis of Sjögren's syndrome	33
Mucosal vitamin D signaling in inflammatory bowel disease	32
Immunological consequences of “immune reconstitution therapy” in multiple sclerosis: A systematic review	32
Autoimmunity in dry eye disease – An updated review of evidence on effector and memory Th17 cells in disease pathogenicity	32
IgA vasculitis in adult patient following vaccination by ChadOx1 nCoV-19	32
Immune checkpoint inhibitors therapies in patients with cancer and preexisting autoimmune diseases: A meta-analysis of observational studies	32
Muscle involvement in myasthenia gravis: Expanding the clinical spectrum of Myasthenia-Myositis association from a large cohort of patients	32
Rhupus: a systematic literature review	31
How to handle patients with autoimmune rheumatic and inflammatory bowel diseases in the COVID-19 era: An expert opinion	31
Environmental risk factors associated with ANCA associated vasculitis: A systematic mapping review	31
Rituximab treatment for IgA vasculitis: A systematic review	30
Severe infections in patients with anti-neutrophil cytoplasmic antibody-associated vasculitides receiving rituximab: A meta-analysis	30
Pregnancy outcome predictors in antiphospholipid syndrome: A systematic review and meta-analysis	30
Eosinophilic granulomatosis with polyangiitis: A review	29
Drug-induced IgA vasculitis in children and adults: Revisiting drug causality using a dual pharmacovigilance-based approach	29
Long-term remission, relapses and maintenance therapy in adult primary central nervous system vasculitis: A single-center 35-year experience	29
Seven recommendations to rescue the patients and reduce the mortality from COVID-19 infection: An immunological point of view	29
Endometriosis and autoimmunity: Can autoantibodies be used as a non-invasive early diagnostic tool?	28
Circadian clock genes as promising therapeutic targets for autoimmune diseases	28
Mesenchymal stromal cells for systemic sclerosis treatment	28
Parkinson's disease is an autoimmune disease: A reappraisal	28
The biology, pathogenetic role, clinical implications, and open issues of serum anti-neutrophil cytoplasmic antibodies	27
Seronegative autoimmune diseases: A challenging diagnosis	27
The immunologic etiology of psychiatric manifestations in systemic lupus erythematosus: A narrative review on the role of the blood brain barrier, antibodies, cytokines and chemokines	27
Autoimmune pre-disease	27
The pathophysiology of polymyalgia rheumatica, small pieces of a big puzzle	26
Engineered antigen-specific regulatory T cells for autoimmune skin conditions	26
Primary Sjögren's syndrome is associated with increased risk of malignancies besides lymphoma: A systematic review and meta-analysis	26
Antibody glycosylation in autoimmune diseases	26
Microorganisms associated to thyroid autoimmunity	26
Fatal COVID-19 infections: Is NK cell dysfunction a link with autoimmune HLH?	26
Autoimmunity in vitiligo: Therapeutic implications and opportunities	26
The COVID-19 pandemic and ANCA-associated vasculitis – reports from the EUVAS meeting and EUVAS education forum	25
Autoantibodies to stratify systemic sclerosis patients into clinically actionable subsets	25
Overview of IgG4-related aortitis and periaortitis. A decade since their first description	25
Anti-rods/rings autoantibody and IMPDH filaments: an update after fifteen years of discovery	25
Regulatory T cell heterogeneity and therapy in autoimmune diseases	25
A proposed role of neutrophil extracellular traps and their interplay with fibroblasts in ANCA-associated vasculitis lung fibrosis	24
T cell abnormalities in systemic sclerosis	24
New insight into the role of exosomes in vitiligo	24
JAK inhibitors and autoimmune rheumatic diseases	24
Hygiene hypothesis and autoimmune diseases: A narrative review of clinical evidences and mechanisms	24
Antiphospholipid antibodies and thrombotic events in COVID-19 patients hospitalized in medicine ward	24
Digital health, big data and smart technologies for the care of patients with systemic autoimmune diseases: Where do we stand?	24
Rituximab for the treatment of eosinophilic granulomatosis with polyangiitis: A systematic literature review	24
Follow-up of COVID-19 patients: LA is transient but other aPLs are persistent	24
Autoimmunity and COVID-19 – The microbiotal connection	23
Polymorphism of toll-like receptor genes and autoimmune endocrine diseases	23
Systemic autoinflammatory disease in adults	23
Microbiota and metabolites in rheumatic diseases	23
The prevalence and incidence rate of pulmonary arterial hypertension in systemic sclerosis: Systematic review and meta-analysis	23
JAK inhibitors and psoriatic arthritis: A systematic review and meta-analysis	23
What can we learn from rapidly progressive interstitial lung disease related to anti-MDA5 dermatomyositis in the management of COVID-19?	23
Comprehensive meta-analysis reveals an association of the HLA-DRB1*1602 allele with autoimmune diseases mediated predominantly by autoantibodies	23
JAK inhibitors and systemic sclerosis: A systematic review of the literature	23
Autoimmune/inflammatory syndrome induced by adjuvants (ASIA) in 2023	23
The myristoylated alanine-rich C-kinase substrates (MARCKS): A membrane-anchored mediator of the cell function	22
Molecular mimicry between SARS-CoV-2 and human proteins	22
Risk factors for hypertension in rheumatoid arthritis patients–A systematic review	22
The revisited role of interleukin-1 alpha and beta in autoimmune and inflammatory disorders and in comorbidities	22
SARS-CoV-2 infection complicated by inflammatory syndrome. Could high-dose human immunoglobulin for intravenous use (IVIG) be beneficial?	21
Risk of COVID-19 in celiac disease patients	21
In utero exposure to Azathioprine in autoimmune disease. Where do we stand?	21
Precision health: A pragmatic approach to understanding and addressing key factors in autoimmune diseases	21
The correlation between SARS-CoV-2 infection and rheumatic disease	21

What is the role of rheumatologists in the era of COVID-19?	21
Ocular microvascular damage in autoimmune rheumatic diseases: The pathophysiological role of the immune system	21
Emerging role of Tissue Resident Memory T cells in vitiligo: From pathogenesis to therapeutics	21
Pathophysiologic role of Interleukin-33/ST2 in Sjögren's syndrome	21
Imatinib might constitute a treatment option for lung involvement in COVID-19	21
Immunomodulatory therapeutic effects of curcumin in rheumatoid arthritis	20
Hepatitis C virus- related cryoglobulinemic vasculitis: A review of the role of the new direct antiviral agents (DAAs) therapy	20
Reactive oxygen species: The Yin and Yang in (auto-)immunity	20
Tumour- associated autoantibodies as prognostic cancer biomarkers- a review	20
Comorbidities and health-related quality of life in Patients with Antineutrophil Cytoplasmic Antibody (ANCA) - associated vasculitis	20
Guillain Barré syndrome and COVID-19: Possible role of the cytokine storm	20
Primary CNS vasculitis: A systematic review on clinical characteristics associated with abnormal biopsy and angiography	19
The autoimmune aetiology of unexplained chronic pain	19
Exosomes as biomarkers and therapeutic delivery for autoimmune diseases: Opportunities and challenges	19
Autoimmune autonomic nervous system imbalance and conditions: Chronic fatigue syndrome, fibromyalgia, silicone breast implants, COVID and post-COVID syndrome, sick building syndrome, post-orthostatic	19
May capillaroscopy be a candidate tool in future algorithms for SSC-ILD: Are we looking for the holy grail? A systematic review	18
Insights into new-onset autoimmune diseases after COVID-19 vaccination	18
Childhood-onset systemic lupus erythematosus-related antiphospholipid syndrome: A multicenter study with 1519 patients	18
Combined Anakinra and Ruxolitinib treatment to rescue extremely ill COVID-19 patients: A pilot study.	18
Factors associated with pulmonary arterial hypertension (PAH) in systemic sclerosis (SSc)	18
Immune-mediated necrotizing myopathy (IMNM): A myopathological challenge	18
Factors associated with fertility abnormalities in women with systemic lupus erythematosus: a systematic review and meta-analysis	18